Cell line · CVCL_1325
Karpas-422
Cancer cell line, Homo sapiens. Diffuse large B-cell lymphoma germinal center B-cell type. 41 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. Karpas-422. Cell lines, record CVCL_1325. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1325
On this page
Cell line
As Cellosaurus gives it.
- Name
- Karpas-422
- Accession
- CVCL_1325
- RRID
- RRID:CVCL_1325
- Synonyms
- KARPAS-422, Karpas 422, KARPAS 422, Karpas422, KARPAS422, K422
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 73Y
- Category
- Cancer cell line
- Diseases
- Diffuse large B-cell lymphoma germinal center B-cell type (NCIt C36080); Diffuse large B-cell lymphoma (ORDO Orphanet_544)
- Derived from
- Pleural effusion (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers41
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor - a preliminary analysis. | Ann Hematol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. | Cancer Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A novel inhibitor of the mitochondrial respiratory complex I with uncoupling properties exerts potent antitumor activity. | Cell Death Dis | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC-driven lymphoma. | EMBO Mol Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. | Sci Adv | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
1 to 10 of 41
See all 41 papersRelatives0
None in this release.
Cell banks4
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| DSMZ | ACC-32 | Discontinued | Cellosaurus |
| ECACC | 06101702 | ECACC | |
| ICLC | HTL99023 | ICLC | |
| Ximbio | 152419 | Ximbio |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1325
GET https://conductscience.org/api/cell-lines/v1/CVCL_1325/papers?page=2